美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

三倍做多標普生物-Direxion

231.99

-11.1000-4.57%

盤後：231.21-0.7800-0.34%19:59 EDT

成交量：29.56萬

成交額：7,010.13萬

市值：6.20億

市盈率：- -

高：244.67

開：241.52

低：230.22

收：243.09

52周最高：341.93

52周最低：102.35

股本：267.45萬

流通股本：267.45萬

量比：0.45

換手率：11.05%

股息：0.90

股息率：0.39%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

商業醫療險迎來行業首版統一示範條款：終結「各自為政」，消費者保護再加碼

世界數據組織設立醫療健康、航運貿易、能源等分支機構

世界數據組織設立醫療健康、航運貿易、能源等分支機構

拜耳（BAYRY）腎病藥物可仁達®獲FDA批新適應症填補1型糖尿病併發症30年空白

醫療板塊市場快訊匯總

健友股份：門冬胰島素雖已獲美國FDA批件暫未實現首單銷售

醫療保健板塊動態：市場快訊綜述

新聞稿：Avalyn任命Robert J. Meyer醫學博士為董事會成員

醫療板塊市場綜述：加密貨幣監管困境、阿斯利康試驗展望與泰國醫院行業前景

美敦力（MDT）：旗下LigaSure™RAS Maryland鉗夾器械獲FDA許可

美敦力Ligasure RAS Maryland設備獲得FDA批准。

九州通、貝因美成立數智醫療健康科技公司

新加坡醫療服務提供商LYC Healthcare IPO定價4美元/股籌資規模上調67%至2500萬美元

新加坡醫療服務提供商LYC Healthcare IPO定價4美元/股籌資規模上調67%至2500萬美元

新加坡醫療服務提供商LYC Healthcare IPO定價4美元/股籌資規模上調67%至2500萬美元

醫療健康板塊市場動態綜述

醫療保健板塊動態匯總：市場快訊

美國人口普查局：2025年，92.1%的美國人在部分時段或全年享有醫療保險。

港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准

鼓勵靈活就業人員參加職工醫保，我國靈活就業人員規模已超過2億人

微博财经-财道工作室

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/LABU/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":231.99,"timestamp":1791835200000,"preClose":243.09,"halted":0,"volume":295561,"hourTrading":{"tag":"盘后","latestPrice":231.21,"preClose":231.99,"latestTime":"19:59 EDT","volume":3834,"amount":888365.3656,"timestamp":1791849594803,"change":-0.78,"changeRate":-0.003362,"amplitude":0.007343},"delay":0,"changeRate":-0.04566210045662098,"floatShares":2674486,"shares":2674486,"eps":0,"marketStatus":"已收盤","change":-11.1,"latestTime":"10-12 16:00:00 EDT","open":241.52,"high":244.6716,"low":230.2215,"amount":70101341.22782,"amplitude":0.059443,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1791878400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":243.09,"sharesOutstanding":3074486,"nav":242.822,"aum":649423578.22,"dividendRate":0.003877,"bidAskSpread":0.002692,"preHourTrading":{"tag":"盘前","latestPrice":242.43,"preClose":243.09,"latestTime":"09:29 EDT","volume":24862,"amount":6085203.2304,"timestamp":1791811795117,"change":-0.66,"changeRate":-0.002715,"amplitude":0.021844},"postHourTrading":{"tag":"盘后","latestPrice":231.21,"preClose":231.99,"latestTime":"19:59 EDT","volume":3834,"amount":888365.3656,"timestamp":1791849594803,"change":-0.78,"changeRate":-0.003362,"amplitude":0.007343},"volumeRatio":0.453297,"impliedVol":0.9772,"impliedVolPercentile":0.7331},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2674486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.453297,"shares":2674486,"dividePrice":0.8994,"high":244.6716,"amplitude":0.059443,"preClose":243.09,"low":230.2215,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":231.99,"eps":0,"divideRate":0.003877,"volume":295561,"delay":0,"ttmEps":0,"open":241.52,"prevYearClose":159.39,"prevWeekClose":243.09,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":257.38,"twentyDayClose":268.39,"sixtyDayClose":265.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668966061","title":"商業醫療險迎來行業首版統一示範條款：終結「各自為政」，消費者保護再加碼","url":"https://stock-news.laohu8.com/highlight/detail?id=2668966061","media":"第一财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668966061?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 18:39","pubTimestamp":1789641540,"startTime":"0","endTime":"0","summary":"商业医疗险即将迎来行业首版统一示范条款。9月16日，中国保险行业协会发布长期医疗险、短期医疗险及城市定制型商业医疗保险示范条款征求意见稿。这是商业医疗险三大品类首次被纳入统一的合同范本框架。多位业内人士指出，这意味着长期“各自为政”的医疗险条款，终于有了统一的“基准线”。正因如此，消费者保护成为本次征求意见稿的重点规范之一。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-09-17/doc-iniscvfv3934997.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-17/doc-iniscvfv3934997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4585","XLV","BK4581","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668696372","title":"世界數據組織設立醫療健康、航運貿易、能源等分支機構","url":"https://stock-news.laohu8.com/highlight/detail?id=2668696372","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668696372?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 17:49","pubTimestamp":1789638576,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159760","BK4588","XLV","BOAT","VHT","IXJ","LABU","BK4550","XBI","BK4581","159945","BK4585","BDRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963286","title":"世界數據組織設立醫療健康、航運貿易、能源等分支機構","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963286","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668963286?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 17:42","pubTimestamp":1789638159,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4581","BOAT","BK4585","BK4550","BDRY","XBI","XLV","VHT","IXJ","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963269","title":"拜耳（BAYRY）腎病藥物可仁達®獲FDA批新適應症 填補1型糖尿病併發症30年空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963269","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668963269?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 17:35","pubTimestamp":1789637756,"startTime":"0","endTime":"0","summary":"本次获批使可仁达成为30多年来首个获批用于治疗1型糖尿病相关慢性肾脏病的创新疗法。这是FDA批准该药的第三个适应症，进一步奠定了其在心肾并发症治疗领域的市场地位。拜耳方面表示，可仁达作为目前唯一获批可同时覆盖1型和2型糖尿病相关慢性肾脏病的口服每日一次MRA药物，将有效填补长期以来的临床空白，并持续巩固公司在心血管及肾脏疾病领域的全球领跑优势。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306150","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4007","BK4588","BK4585","BAYRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186669077","title":"醫療板塊市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1186669077","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186669077?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 16:21","pubTimestamp":1789633280,"startTime":"0","endTime":"0","summary":"英科医疗正日益成为定价和运营效率的标杆。尽管中国手套平均售价近期上涨使马来西亚生产商得以跟风提价，但其结构性成本劣势仍持续拖累竞争力。她补充道，若马来西亚厂商继续主要依靠产量和价格竞争，可能面临市场份额进一步流失的风险，这凸显了加大创新和产品差异化以捍卫利润率的必要性。Public IB将马来西亚橡胶手套板块评级从\"中性\"下调至\"减持\"。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","XBI","XLV","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668930403","title":"健友股份：門冬胰島素雖已獲美國FDA批件 暫未實現首單銷售","url":"https://stock-news.laohu8.com/highlight/detail?id=2668930403","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668930403?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 10:25","pubTimestamp":1789611935,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149246717","title":"醫療保健板塊動態：市場快訊綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1149246717","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149246717?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 05:13","pubTimestamp":1789593236,"startTime":"0","endTime":"0","summary":"美东时间下午3点28分——Q/C Technologies股价本周三尾盘强势拉升，涨幅一度超过一倍，从周一暴跌67%及周二触及52周低点的阴霾中大幅反弹。这家光学计算公司上周五晚间披露，与Martin Shkreli关联实体及OpenAI科学家Chelsea Voss的咨询协议已双方同意终止，Voss同时辞去董事会职务。该股最新报1.06美元，上涨139%，交投高度波动，但仍低于上周五收盘价1.71美元。分析师补充道，中东患者的积压需求以及7月起柬埔寨患者收入从低基数逐步正常化，应能提振泰国医院板块。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XLV","LABU","BK4588","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123407353","title":"新聞稿：Avalyn任命Robert J. Meyer醫學博士為董事會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=1123407353","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123407353?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 04:02","pubTimestamp":1789588975,"startTime":"0","endTime":"0","summary":"波士顿，2026年9月16日——Avalyn Pharma Inc.是一家处于临床阶段的生物制药公司，致力于开创吸入式疗法，以变革严重罕见呼吸系统疾病的治疗模式。该公司今日宣布，任命杰出肺病专家、美国食品药品监督管理局前高级领导者RobertJ. Meyer医学博士为其董事会成员。Meyer博士最近曾担任Greenleaf Health药品与生物制品部门负责人。Meyer博士拥有超过25年的领导经验，涵盖监管、学术和行业领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4007","LABU","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180333334","title":"醫療板塊市場綜述：加密貨幣監管困境、阿斯利康試驗展望與泰國醫院行業前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1180333334","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180333334?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 00:24","pubTimestamp":1789575886,"startTime":"0","endTime":"0","summary":"今日医疗板块市场动态纷呈，多则重要消息牵动投资者神经。2350 ET - 星展集团研究分析师在一份报告中指出，得益于呼吸道疾病病例增加和中东地区积压需求等因素，泰国医院行业下半年业绩可能强于上半年。分析师补充道，来自中东患者的积压需求以及柬埔寨患者收入从7月份开始从低基数常态化，应能提振泰国医院行业。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LABU","XLV","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667598338","title":"美敦力（MDT）：旗下LigaSure™RAS Maryland鉗夾器械獲FDA許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2667598338","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667598338?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 20:09","pubTimestamp":1789560557,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美敦力（MDT）宣布，其用于Hugo™机器人辅助手术（RAS）系统的LigaSure™RAS Maryland钳夹器械已获得美国食品药品监督管理局（FDA）的许可。据悉，该器械是首款由机器人驱动的LigaSure器械，需与Valleylab™FT10能量平台配合使用，能在约2秒内完成对直径达7毫米的血管、厚组织及淋巴管的密封与切割，并有效减少热扩散。作为美敦力旗下的核心血管封闭技术，LigaSure此前已在欧洲推出并应用于全球超4500万例手术。本次获批将进一步丰富Hugo系统在美国的手术器械组合，助力外科医生将成熟的能量器械无缝引入机器人手术流程中。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NjkwOTdhNzcyN2U0YmYwYmQ0MTU5ZmNlZDZlMGU5OTExMDg1MTQ4NjI3MDM=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjkwOTdhNzcyN2U0YmYwYmQ0MTU5ZmNlZDZlMGU5OTExMDg1MTQ4NjI3MDM=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306112","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2028103732.USD","LU1506573853.SGD","LU2089283258.USD","LU2111349929.HKD","LU0211326839.USD","LU0211326755.USD","LU0432979614.USD","LU1116320901.HKD","LU1989771016.USD","IE00BGHQF631.EUR","LU0496365809.HKD","LU0265550359.USD","LU1116320737.USD","LU1057294990.SGD","LU1291159041.SGD","LU0162691827.USD","IE00BVYPNV92.GBP","LABU","LU0265550946.USD","LU0158827948.USD","LU1244550577.SGD","LU2112291526.USD","LU2023251221.USD","LU1571399168.USD","IE00B42XCP33.USD","LU0072461881.USD","LU2089284900.SGD","IE00BQXX3D17.EUR","BK4585","LU0976567544.SGD","BK4588","LU1989764748.USD","IE00BQXX3F31.USD","LU0106261372.USD","LU2271345857.HKD","LU1023059063.AUD","LU0006306889.USD","BK4082","LU0211331839.USD","LU1989764664.SGD","IE00BDGV0183.EUR","LU0320765489.SGD","IE000M9KFDE8.USD","IE00BFXG1179.USD","IE00BQXX3C00.GBP","MDT","LU1061106388.HKD","LU0122379950.USD","LU0208291251.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667276602","title":"美敦力Ligasure RAS Maryland設備獲得FDA批准。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667276602","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667276602?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 18:31","pubTimestamp":1789554678,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667603419","title":"九州通、貝因美成立數智醫療健康科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2667603419","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667603419?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 15:34","pubTimestamp":1789544041,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XLV","XBI","BK4585","BK4581","BK4588","BK4550","VHT","IXJ","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667158608","title":"新加坡醫療服務提供商LYC Healthcare IPO定價4美元/股 籌資規模上調67%至2500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667158608","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667158608?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 14:57","pubTimestamp":1789541822,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在新加坡运营医疗诊所和骨科手术中心的LYC Healthcare于周二提高了即将进行的首次公开募股的拟议发行规模。该公司目前计划发行630万股股票，拟议发行价为每股4美元，以筹集2500万美元。此前，公司已提交文件，计划发行300万股，发行价区间为每股4至6美元。按照调整后的发行规模，LYC Healthcare预计募资金额将较此前预期高出67%，对应市值将达到1.37亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260916/32371585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4581","BK4588","UDN","XLV","XBI","MEDX","BK4585","STmain","UUP","LABU","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667670478","title":"新加坡醫療服務提供商LYC Healthcare IPO定價4美元/股 籌資規模上調67%至2500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667670478","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667670478?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 14:28","pubTimestamp":1789540088,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在新加坡运营医疗诊所和骨科手术中心的LYC Healthcare于周二提高了即将进行的首次公开募股的拟议发行规模。按照调整后的发行规模，LYC Healthcare预计募资金额将较此前预期高出67%，对应市值将达到1.37亿美元。LYC Healthcare成立于2017年，是一家位于新加坡的多学科专科医疗服务提供商，通过两家运营子公司、5家医疗诊所以及内部先进影像设施，提供一体化的肌肉骨骼医疗服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["XBI","XLV","UUP","IPOS","UDN","BK4588","MEDX","BK4581","STmain","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667670424","title":"新加坡醫療服務提供商LYC Healthcare IPO定價4美元/股 籌資規模上調67%至2500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667670424","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667670424?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 14:28","pubTimestamp":1789540088,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","BK4588","UUP","XBI","XLV","UDN","BK4581","IPOS","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142651526","title":"醫療健康板塊市場動態綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1142651526","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142651526?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 04:52","pubTimestamp":1789505567,"startTime":"0","endTime":"0","summary":"医疗健康领域最新市场快讯，涵盖多家药企与医疗器械公司的股价波动与分析师观点。市场表现方面，阿斯利康股价上涨2.25%，报163.78美元。该股目前下跌1.9%，报113.20瑞郎。杰富瑞对Immutep转持看多立场，分析师David Stanton认为这家生物技术公司的主要候选药物有了更清晰的发展路径。Stanton将评级从持有上调至买入，对该澳大利亚公司关于肺癌研究提前终止似乎与临床因素或试验执行无关的更新感到鼓舞。杰富瑞将目标价翻倍至8澳分。该股持平于4.7澳分。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4585","BK4588","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146582906","title":"醫療保健板塊動態匯總：市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1146582906","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146582906?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 00:22","pubTimestamp":1789489368,"startTime":"0","endTime":"0","summary":"贝伦贝格的分析师在最新研报中指出，阿斯利康拥有强劲且多元化的产品组合，其研发管线蕴藏着巨大的潜力。他们认为，这家制药巨头当前管线项目有望实现13%的研发投资回报率。尽管2026年一些备受期待的研究结果遭遇挫折，但这些失利已被其他积极成果所抵消，这恰恰凸显了多元化投资组合的重要性。截至发稿，阿斯利康股价上涨2.25%，报163.78美元。该股持平于4.7澳分。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XLV","BK4585","LABU","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667628604","title":"美國人口普查局：2025年，92.1%的美國人在部分時段或全年享有醫療保險。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667628604","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667628604?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 22:09","pubTimestamp":1789481360,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["XBI","BK4581","BK4585","BK4588","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667619385","title":"港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667619385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667619385?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 13:36","pubTimestamp":1789450580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B午后飙升逾17%。消息面上，礼邦医药近日宣布，AP308用于治疗IgA肾病的新药临床试验申请近日获美国食品药品监督管理局批准。公司计划于近期启动AP308的首次人体临床试验。AP308的IND获批标志着这一首创新药由临床前研究迈入临床开发阶段。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","09637","LABU","KCAI","BK1191","VXUS","09939","159938","BK4585","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691484","title":"鼓勵靈活就業人員參加職工醫保，我國靈活就業人員規模已超過2億人","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691484","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691484?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:42","pubTimestamp":1789429320,"startTime":"0","endTime":"0","summary":"来源：@21世纪经济报道微博#灵活就业人员买医保更便利了#“鼓励无雇工的个体工商户、未在用人单位参加职工基本医疗保险的非全日制从业人员以及其他灵活就业人员参加职工基本医疗保险。具体办法由国务院医疗保障行政部门会同国务院有关部门制定。”而根据测算，我国灵活就业人员规模已超过2亿人。于保荣说，医疗保障法“鼓励”灵活就业人员参加职工医保，意味着国家倡导灵活就业人员优先选择参加职工医保。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-15/doc-inirwfqa8816026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","XLV","BK4588","BK4581","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}